121 related articles for article (PubMed ID: 1419285)
1. 4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer.
Coombes RC; Hughes SW; Dowsett M
Eur J Cancer; 1992; 28A(12):1941-5. PubMed ID: 1419285
[TBL] [Abstract][Full Text] [Related]
2. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer.
Coombes RC; Goss P; Dowsett M; Gazet JC; Brodie A
Lancet; 1984 Dec; 2(8414):1237-9. PubMed ID: 6150277
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.
Höffken K; Jonat W; Possinger K; Kölbel M; Kunz T; Wagner H; Becher R; Callies R; Friederich P; Willmanns W
J Clin Oncol; 1990 May; 8(5):875-80. PubMed ID: 2185341
[TBL] [Abstract][Full Text] [Related]
4. 4-Hydroxyandrostenedione treatment for postmenopausal patients with breast cancer.
Coombes RC
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):145-8. PubMed ID: 1525056
[TBL] [Abstract][Full Text] [Related]
5. Formestane in the treatment of advanced postmenopausal breast cancer.
Possinger K; Jonat W; Höffken K
Ann Oncol; 1994; 5 Suppl 7():S7-10. PubMed ID: 7873464
[TBL] [Abstract][Full Text] [Related]
6. Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione.
Stein RC; Dowsett M; Hedley A; Davenport J; Gazet JC; Ford HT; Coombes RC
Cancer Chemother Pharmacol; 1990; 26(1):75-8. PubMed ID: 2322991
[TBL] [Abstract][Full Text] [Related]
7. 4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer.
Coombes RC; Goss PE; Dowsett M; Hutchinson G; Cunningham D; Jarman M; Brodie AM
Steroids; 1987; 50(1-3):245-52. PubMed ID: 3504062
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
Goss PE; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Gazet JC; Coombes RC
Cancer Res; 1986 Sep; 46(9):4823-6. PubMed ID: 2942241
[TBL] [Abstract][Full Text] [Related]
9. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.
Dowsett M; Goss PE; Powles TJ; Hutchinson G; Brodie AM; Jeffcoate SL; Coombes RC
Cancer Res; 1987 Apr; 47(7):1957-61. PubMed ID: 3815384
[TBL] [Abstract][Full Text] [Related]
10. Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer.
Cunningham D; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Ford HT; Gazet JC; Coombes RC
Cancer Chemother Pharmacol; 1987; 20(3):253-5. PubMed ID: 3677299
[TBL] [Abstract][Full Text] [Related]
11. Second generation aromatase inhibitor--4-hydroxyandrostenedione.
Dowsett M; Coombes RC
Breast Cancer Res Treat; 1994; 30(1):81-7. PubMed ID: 7949207
[TBL] [Abstract][Full Text] [Related]
12. An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients.
Dowsett M; Mehta A; King N; Smith IE; Powles TJ; Stein RC; Coombes RC
Eur J Cancer; 1992; 28(2-3):415-20. PubMed ID: 1591054
[TBL] [Abstract][Full Text] [Related]
13. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.
Dowsett M; Cunningham DC; Stein RC; Evans S; Dehennin L; Hedley A; Coombes RC
Cancer Res; 1989 Mar; 49(5):1306-12. PubMed ID: 2917360
[TBL] [Abstract][Full Text] [Related]
14. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients.
Jones AL; MacNeill F; Jacobs S; Lonning PE; Dowsett M; Powles TJ
Eur J Cancer; 1992; 28A(10):1712-6. PubMed ID: 1389491
[TBL] [Abstract][Full Text] [Related]
15. Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.
Johannessen DC; Adlercreutz H; Fotsis T; Lønning PE
Br J Cancer; 1993 Aug; 68(2):393-8. PubMed ID: 8135918
[TBL] [Abstract][Full Text] [Related]
16. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
Stein RC; Dowsett M; Hedley A; Gazet JC; Ford HT; Coombes RC
Br J Cancer; 1990 Oct; 62(4):679-83. PubMed ID: 2145964
[TBL] [Abstract][Full Text] [Related]
17. Formestane: effective therapy in postmenopausal women with advanced breast cancer.
Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Martinetti A; Ferrari L; Bartoli C; Sacchini V; Attili A; Lepera P
Ann Oncol; 1994; 5 Suppl 7():S15-7. PubMed ID: 7873456
[TBL] [Abstract][Full Text] [Related]
18. A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.
Kleeberg UR; Dowsett M; Carrion RP; Dodwell DJ; Vorobiof DA; Aparicio LA; Robertson JF
Oncology; 1997; 54 Suppl 2():19-22. PubMed ID: 9394856
[TBL] [Abstract][Full Text] [Related]
19. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients.
MacNeill FA; Jacobs S; Dowsett M; Lonning PE; Powles TJ
Cancer Chemother Pharmacol; 1995; 36(3):249-54. PubMed ID: 7781147
[TBL] [Abstract][Full Text] [Related]
20. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group.
Bajetta E; Zilembo N; Barni S; Noberasco C; Martinetti A; Ferrari L; Schieppati G; Buzzoni R; Jirillo A; Amichetti M; D'Aprile M; Comella G; Bichisao E; Bolelli GF; Attili A; Bombardieri E
Ann Oncol; 1997 Jul; 8(7):649-54. PubMed ID: 9296217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
